FDA responds to provider pressure, backs off stricter control of fecal transplants for C. diff

Share this article:

Individuals with treatment-resistant Clostridium difficile can undergo fecal transplants after giving informed consent, the Food and Drug Administration recently announced. This is a victory for providers, who pushed back after the FDA recently announced it would tighten regulations around the transplants. 

Fecal microbiota transplants (FMTs) treat C. diff by repopulating the gut with necessary bacteria that was wiped out by antibiotics.

Arguing that transplants been well-established as an effective and safe means of treating serious cases of C. diff, healthcare providers and groups such as the American Gastroenterological Association pushed back vigorously against FDA efforts to require investigational new drug (IND) approval to do transplants. They said IND approval requires an arduous process, and would prevent patients from obtaining needed transplants in a timely manner.

“The agency acknowledges these concerns and intends to exercise enforcement discretion regarding the IND requirements for the use of FMT to treat C. difficile infection,” the FDA announced Tuesday. Physicians can provide these transplants after sharing potential risks and obtaining informed consent from the patient or a patient's legal representative.

Colleen R. Kelly, M.D., Clinical Assistant Professor of Medicine, Warren Alpert Medical School of Brown University, is a principal investigator for the first U.S. clinical trial of FMTs to treat relapsing C. difficile infection. Doctors had been performing FMTs for decades before studies like this one drew the FDA's attention to transplants, she told McKnight's.

Providers should not be scared off by the administration's scrutiny of the procedure, she stressed.

With rigorous donor screening protocols and other precautions in place, fecal transplant has proven to be a safe C. diff treatment, Kelly said. A quarter to a third of her patients are from long-term care facilities, she estimated.

The FDA's main concerns are with fecal transplants used to treat more complicated conditions than C. diff, such as Crohn's disease, Kelly surmises. The agency is likely also concerned about for-profit transplant providers, who will do the procedure on practically anyone for a fee, she said.

The FDA will remain cautious about transplants, but the latest announcement is “as much of a green light as you're going to get from them,” she said.

Click here to access the complete FDA statement.

Share this article:

More in News

Long-term care continues to lead in deal volume and value: PwC report

Long-term care continues to lead in deal volume ...

Long-term care bucked healthcare industry trends with strong merger and acquisition activity in the second quarter of 2014, according to newly released data from professional services firm PricewaterhouseCoopers.

Empowering nurse practitioners could reduce hospitalizations from SNFs, study finds

Granting more authority to nurse practitioners is associated with reduced hospitalization of skilled nursing facility residents, according to recently published findings.

Pioneer ACO drops out of program, despite reductions in skilled nursing utilization

A California healthcare system has become the latest dropout from the Pioneer Accountable Care Organization program, despite reducing skilled nursing facility utilization and improving its readmission rates. Sharp HealthCare announced its decision in a quarterly financial statement released Tuesday.